These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 26474755)

  • 1. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
    Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
    English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
    Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
    Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
    Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
    Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
    El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
    Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
    Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
    PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
    Menderes G; Bonazzoli E; Bellone S; Black J; Predolini F; Pettinella F; Masserdotti A; Zammataro L; Altwerger G; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Clin Cancer Res; 2017 Oct; 23(19):5836-5845. PubMed ID: 28679774
    [No Abstract]   [Full Text] [Related]  

  • 10. Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110.
    Witthauer J; Schlereth B; Brischwein K; Winter H; Funke I; Jauch KW; Baeuerle P; Mayer B
    Breast Cancer Res Treat; 2009 Oct; 117(3):471-81. PubMed ID: 18819003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes.
    Schmitt M; Schmitt A; Reinhardt P; Thess B; Manfras B; Lindhofer H; Riechelmann H; Wiesneth M; Gronau S
    Int J Oncol; 2004 Oct; 25(4):841-8. PubMed ID: 15375531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
    Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R
    Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.
    Cioffi M; Dorado J; Baeuerle PA; Heeschen C
    Clin Cancer Res; 2012 Jan; 18(2):465-74. PubMed ID: 22096026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
    Richter CE; Cocco E; Bellone S; Silasi DA; Rüttinger D; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2010 Dec; 203(6):582.e1-7. PubMed ID: 20870202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
    Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
    BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.
    Oberg HH; Janitschke L; Sulaj V; Weimer J; Gonnermann D; Hedemann N; Arnold N; Kabelitz D; Peipp M; Bauerschlag D; Wesch D
    J Leukoc Biol; 2020 Jun; 107(6):1081-1095. PubMed ID: 31833593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro.
    Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M; Morisaki T
    Anticancer Res; 2014 Aug; 34(8):4509-19. PubMed ID: 25075094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
    Ren-Heidenreich L; Davol PA; Kouttab NM; Elfenbein GJ; Lum LG
    Cancer; 2004 Mar; 100(5):1095-103. PubMed ID: 14983507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.
    Carrara L; Guzzo F; Roque DM; Bellone S; Emiliano C; Sartori E; Pecorelli S; Schwartz PE; Rutherford TJ; Santin AD
    Gynecol Oncol; 2012 Apr; 125(1):231-6. PubMed ID: 22209775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.
    Petsch S; Gires O; Rüttinger D; Denzel S; Lippold S; Baeuerle PA; Wolf A
    MAbs; 2011; 3(1):31-7. PubMed ID: 21107020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.